Upon completion of the activity, participants should be able to:
1. Answer patient questions about the differences between biologics and small-molecule drugs
2. Explain the FDA process for the evaluation of post approval changes for reference biologics, and how this relates to biosimilars
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.